Literature DB >> 20514789

Effect of thalidomide on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells.

Eunkyue Park1, William R Levis, Nigel Greig, Euisun Jung, Georgia Schuller-Levis.   

Abstract

Thalidomide is anti-inflammatory under some conditions, yet has been reported to up-regulate Th1 (T helper 1) immunity measured by increased IL-2 (Interleukin-2) and gamma interferon. The authors have assessed the effect of thalidomide and analogues, di- and tri-thiothalidomide, on a lipopolysaccharide (LPS) activated macrophage cell line (RAW 246.7 cells). The authors' findings showed that nitric oxide (NO) was significantly inhibited by thalidomide (15%) and its analogues (di-thiothalidomide; 15%, tri-thiothalidomide; 32%). The proinflammatory molecules TNF-alpha (tumor necrosis factor-alpha) and IL-6 were not significantly inhibited. Pretreatment with thalidomide and analogues before activation was not different from simultaneous treatment. Inhibition of inducible nitric oxide synthase (iNOS) may prove to be an important target for the anti-inflammatory and anti-cancer effects of thalidomide and related immunomodulatory drugs (IMiDs).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514789      PMCID: PMC4807434     

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  27 in total

1.  Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.

Authors:  Patrick A J Haslett; Paul Roche; C Ruth Butlin; Murdo Macdonald; Niraj Shrestha; Rakesh Manandhar; Joe Lemaster; Rachel Hawksworth; Mahesh Shah; A Steven Lubinsky; Matthew Albert; Jason Worley; Gilla Kaplan
Journal:  J Infect Dis       Date:  2005-11-10       Impact factor: 5.226

2.  Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme.

Authors:  K Varma; A Y Finlay
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

Review 3.  Thalidomide: dermatological indications, mechanisms of action and side-effects.

Authors:  J J Wu; D B Huang; K R Pang; S Hsu; S K Tyring
Journal:  Br J Dermatol       Date:  2005-08       Impact factor: 9.302

4.  Taurine chloramine inhibits inducible nitric oxide synthase and TNF-alpha gene expression in activated alveolar macrophages: decreased NF-kappaB activation and IkappaB kinase activity.

Authors:  M Barua; Y Liu; M R Quinn
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

5.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  J M Jacobson; J S Greenspan; J Spritzler; N Ketter; J L Fahey; J B Jackson; L Fox; M Chernoff; A W Wu; L A MacPhail; G J Vasquez; D A Wohl
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

6.  Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide.

Authors:  Edward Shannon; Robert Noveck; Felipe Sandoval; Burde Kamath
Journal:  Immunopharmacol Immunotoxicol       Date:  2008       Impact factor: 2.730

Review 7.  TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.

Authors:  David Tweedie; Kumar Sambamurti; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2007-09       Impact factor: 3.498

8.  Development and biological evaluation of C(60) fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent.

Authors:  Sheng-Tung Huang; Chia-Shin Ho; Chun-Mao Lin; Hsu-Wei Fang; Yi-Xiang Peng
Journal:  Bioorg Med Chem       Date:  2008-08-07       Impact factor: 3.641

9.  Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity.

Authors:  Xiaoxiang Zhu; Tony Giordano; Qian-Sheng Yu; Harold W Holloway; Tracy Ann Perry; Debomoy K Lahiri; Arnold Brossi; Nigel H Greig
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

10.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.

Authors:  E P Sampaio; E N Sarno; R Galilly; Z A Cohn; G Kaplan
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more
  5 in total

1.  Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity.

Authors:  Weiming Luo; Qian-sheng Yu; Isidro Salcedo; Harold W Holloway; Debomoy K Lahiri; Arnold Brossi; David Tweedie; Nigel H Greig
Journal:  Bioorg Med Chem       Date:  2011-05-23       Impact factor: 3.641

2.  Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.

Authors:  Nicholas G Theodorakis; Yining N Wang; Vyacheslav A Korshunov; Mary A Maluccio; Nicholas J Skill
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

3.  Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity.

Authors:  Frank Martiniuk; Jerome Giovinazzo; Ainah U Tan; Rozana Shahidullah; Patrick Haslett; Gilla Kaplan; William R Levis
Journal:  J Drugs Dermatol       Date:  2012-05       Impact factor: 2.114

4.  Thalidomide Analogues Suppress Lipopolysaccharide-Induced Synthesis of TNF-α and Nitrite, an Intermediate of Nitric Oxide, in a Cellular Model of Inflammation.

Authors:  David Tweedie; Kathryn A Frankola; Weiming Luo; Yazhou Li; Nigel H Greig
Journal:  Open Biochem J       Date:  2011-07-19

5.  Protective Effects of Thalidomide on High-Glucose-Induced Podocyte Injury through In Vitro Modulation of Macrophage M1/M2 Differentiation.

Authors:  Hui Liao; Yuanping Li; Xilan Zhang; Xiaoyun Zhao; Dan Zheng; Dayue Shen; Rongshan Li
Journal:  J Immunol Res       Date:  2020-08-27       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.